

## DAFTAR PUSTAKA

- [1] H. Sung *et al.*, “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” *CA. Cancer J. Clin.*, vol. 71, no. 3, pp. 209–249, 2021, doi: 10.3322/caac.21660.
- [2] J. Didkowska, U. Wojciechowska, M. Mańczuk, and J. Lobaszewski, “Lung cancer epidemiology: Contemporary and future challenges worldwide,” *Ann. Transl. Med.*, vol. 4, no. 8, pp. 1–11, 2016, doi: 10.21037/atm.2016.03.11.
- [3] M. Reck *et al.*, “Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy,” *Lung Cancer*, vol. 148, pp. 159–165, 2020, doi: 10.1016/j.lungcan.2020.08.004.
- [4] P. M. de Groot, C. C. Wu, B. W. Carter, and R. F. Munden, “The epidemiology of lung cancer,” *Transl. Lung Cancer Res.*, vol. 7, no. 3, pp. 220–233, 2018, doi: 10.21037/tlcr.2018.05.06.
- [5] C. B. Blackadar, “Historical review of the causes of cancer,” *World J. Clin. Oncol.*, vol. 7, no. 1, pp. 54–86, 2016, doi: 10.5306/wjco.v7.i1.54.
- [6] World Health Organization, “Cancer Incident in Indonesia,” *Int. Agency Res. Cancer*, vol. 858, pp. 1–2, 2020.
- [7] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” *CA. Cancer J. Clin.*, vol. 68, no. 6, pp. 394–424, 2018, doi: 10.3322/caac.21492.
- [8] T. Berghmans *et al.*, “European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer,” *Lung Cancer*, vol. 150, pp. 221–239, 2020, doi: 10.1016/j.lungcan.2020.08.017.
- [9] H. Lemjabbar-Alaoui, O. U. I. Hassan, Y. W. Yang, and P. Buchanan, “Lung cancer: Biology and treatment options,” *Biochim. Biophys. Acta - Rev. Cancer*, vol. 1856, no. 2, pp. 189–210, 2015, doi: 10.1016/j.bbcan.2015.08.002.
- [10] R. L. Soiza, A. I. C. Donaldson, and P. K. Myint, “Vaccine against



- arteriosclerosis: an update,” *Ther. Adv. Vaccines*, vol. 9, no. 6, pp. 259–261, 2018, doi: 10.1177/https.
- [11] S. Gianfaldoni, R. Gianfaldoni, U. Wollina, J. Lotti, G. Tchernev, and T. Lotti, “An overview on radiotherapy: From its history to its current applications in dermatology,” *Open Access Maced. J. Med. Sci.*, vol. 5, no. 4 Special Issue GlobalDermatology, pp. 521–525, 2017, doi: 10.3889/oamjms.2017.122.
- [12] O. Mohamad *et al.*, “Carbon ion radiotherapy: A review of clinical experiences and preclinical research, with an emphasis on DNA damage/repair,” *Cancers (Basel)*, vol. 9, no. 6, pp. 1–30, 2017, doi: 10.3390/cancers9060066.
- [13] O. Mohamad, H. Makishima, and T. Kamada, “Evolution of carbon ion radiotherapy at the national institute of radiological sciences in Japan,” *Cancers (Basel)*, vol. 10, no. 3, 2018, doi: 10.3390/cancers10030066.
- [14] J. A. Nickoloff, “Photon, light ion, and heavy ion cancer radiotherapy: Paths from physics and biology to clinical practice,” *Ann. Transl. Med.*, vol. 3, no. 21, pp. 1–6, 2015, doi: 10.3978/j.issn.2305-5839.2015.12.18.
- [15] T. D. Malouff, A. Mahajan, S. Krishnan, C. Beltran, D. S. Seneviratne, and D. M. Trifiletti, “Carbon Ion Therapy: A Modern Review of an Emerging Technology,” *Front. Oncol.*, vol. 10, no. February, pp. 1–13, 2020, doi: 10.3389/fonc.2020.00082.
- [16] J. Kim, J. M. Park, and H.-G. Wu, “Carbon Ion Therapy: A Review of an Advanced Technology,” *Prog. Med. Phys.*, vol. 31, no. 3, pp. 71–80, 2020, doi: 10.14316/pmp.2020.31.3.71.
- [17] R. Rami-Porta, “Future perspectives on the tnm staging for lung cancer,” *Cancers (Basel)*, vol. 13, no. 8, pp. 1–13, 2021, doi: 10.3390/cancers13081940.
- [18] I. Nurfatthan, “Analisis Dosis dan Waktu Terapi Pada Terapi Kanker Paru-Paru Berbasis Terapi Ion dan Boron Neutron Capture Therapy Menggunakan Program PHITS,” *Univ. Gadjah Mada*, 2019.
- [19] J. Jeong and J. O. Deasy, “Estimation of Clinical Relative Biological Effect



- (cRBE) of Carbon Ion Radiation Therapy (CIRT) for Early Stage Lung Cancer Based on Mechanistic Tumor Response Modeling,” *Int. J. Radiat. Oncol.*, vol. 105, no. 1, p. S7, 2019, doi: 10.1016/j.ijrobp.2019.06.391.
- [20] F. Romano *et al.*, “A Monte Carlo study for the calculation of the average linear energy transfer (LET) distributions for a clinical proton beam line and a radiobiological carbon ion beam line,” *Phys. Med. Biol.*, vol. 59, no. 12, pp. 2863–2882, 2014, doi: 10.1088/0031-9155/59/12/2863.
- [21] Y. Miyasaka *et al.*, “Comparison of oncologic outcomes between carbon ion radiotherapy and stereotactic body radiotherapy for early-stage non-small cell lung cancer,” *Cancers (Basel)*, vol. 13, no. 2, pp. 1–12, 2021, doi: 10.3390/cancers13020176.
- [22] O. Fujii *et al.*, “A retrospective comparison of proton therapy and carbon ion therapy for stage i non-small cell lung cancer,” *Radiother. Oncol.*, vol. 109, no. 1, pp. 32–37, 2013, doi: 10.1016/j.radonc.2013.08.038.
- [23] N. Yamamoto *et al.*, “A Dose Escalation Clinical Trial of Single-Fraction Carbon Ion Radiotherapy for Peripheral Stage I Non-Small Cell Lung Cancer,” *J. Thorac. Oncol.*, vol. 12, no. 4, pp. 673–680, 2017, doi: 10.1016/j.jtho.2016.12.012.
- [24] M. Nakajima *et al.*, “Carbon-ion radiotherapy for non-small cell lung cancer with interstitial lung disease: A retrospective analysis,” *Radiat. Oncol.*, vol. 12, no. 1, pp. 1–9, 2017, doi: 10.1186/s13014-017-0881-1.
- [25] N. Ono, T. Yamamoto, Y. Nomoto, A. Nakajima, M. Isozaki, and K. Kasuya, G. Ishikawa, H. Nemoto, “Long Term Results of Single-Fraction Carbon-Ion Radiotherapy,” pp. 1–11, 2021.
- [26] K. Shirai *et al.*, “Clinical outcomes using carbon-ion radiotherapy and dose-volume histogram comparison between carbon-ion radiotherapy and photon therapy for T2b-4N0M0 non-small cell lung cancer-A pilot study,” *PLoS One*, vol. 12, no. 4, pp. 1–14, 2017, doi: 10.1371/journal.pone.0175589.
- [27] L. Ma *et al.*, “A current review of dose-escalated radiotherapy in locally advanced non-small cell lung cancer,” *Radiol. Oncol.*, vol. 53, no. 1, pp. 6–14, 2019, doi: 10.2478/raon-2019-0006.



- [28] S. Mori, Y. Takei, T. Shirai, Y. Hara, and T. Furukawa, “Scanned carbon-ion beam therapy throughput over the first 7 years at National Institute of Radiological Sciences,” *Phys. Medica*, vol. 52, no. June, pp. 18–26, 2018, doi: 10.1016/j.ejmp.2018.06.002.
- [29] Y. Kubota, M. Sakai, M. Tashiro, J. Saitoh, T. Abe, and T. Nakano, “Technical Note: Predicting dose distribution with replacing stopping power ratio for inter-fractional motion and intra-fractional motion during carbon ion radiotherapy with passive irradiation method for stage I lung cancer,” *Med. Phys.*, vol. 45, no. 7, pp. 3435–3441, 2018, doi: 10.1002/mp.12966.
- [30] A. E. Paz, N. Yamamoto, M. Sakama, N. Matsufuji, and T. Kanai, “Tumor Control Probability Analysis for Single-Fraction Carbon-Ion Radiation Therapy of Early-Stage Non-small Cell Lung Cancer,” *Int. J. Radiat. Oncol. Biol. Phys.*, vol. 102, no. 5, pp. 1551–1559, 2018, doi: 10.1016/j.ijrobp.2018.07.2009.
- [31] J. Saitoh, “Hypofractionated carbon - ion radiotherapy for stage I peripheral nonsmall cell lung cancer ( GUNMA0701 ): Prospective phase II study,” no. September, pp. 6644–6650, 2019, doi: 10.1002/cam4.2561.
- [32] J. E. Cotes, D. J. Chinn, and M. R. Miller, *Lung Function*, 6th ed. 2006.
- [33] H. H. Aung, A. Sivakumar, S. K. Gholami, S. P. Venkateswaran, B. Gorain, and Shadab, *An Overview of the Anatomy and Physiology of the Lung*. Elsevier Inc., 2019.
- [34] PDQ Cancer Information Summaries [Internet], *PDQ Adult Treatment Editorial Board. Non-Small Cell Lung Cancer Treatment (PDQ®): Health Professional Version*. Bethesda (MD): National Cancer Institute (US): PDQ Cancer Information Summaries [Internet], 2021.
- [35] W. Yan, I. I. Wistuba, M. R. Emmert-buck, and H. S. Erickson, “SCC highlights and insights,” *Am J Cancer Res*, vol. 1, no. 3, pp. 275–300, 2011.
- [36] P. C. I. S. [Internet]. B. (MD): N. C. I. (US, *PDQ Adult Treatment Editorial Board. Non-Small Cell Lung Cancer Treatment (PDQ®): Patient Version*. Bethesda (MD): National Cancer Institute (US): PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US, 2021.



- [37] Y. Demizu, O. Fujii, H. Iwata, and N. Fuwa, “Carbon Ion Therapy for Early-Stage Non-Small-Cell Lung Cancer,” *Biomed Res. Int.*, vol. 2014, 2014, doi: 10.1155/2014/727962.
- [38] Podgoršak E.B., “Interactions of Charged Particles with Matter,” *Radiat. Phys. Med. Phys.*, pp. 227–275, 2009, doi: 10.1007/978-3-642-00875-7\_6.
- [39] N. G. Burnet, S. J. Thomas, K. E. Burton, and S. J. Jefferies, “Defining the tumour and target volumes for radiotherapy,” *Cancer Imaging*, vol. 4, no. 2, pp. 153–161, 2004, doi: 10.1102/1470-7330.2004.0054.
- [40] IAEA and ICRU, “Relative Biological Effectiveness in Ion Beam Therapy,” *IAEA Tech. Reports*, no. 461, pp. 1–165, 2008, [Online]. Available: [http://www-pub.iaea.org/MTCD/publications/PDF/trs461\\_web.pdf](http://www-pub.iaea.org/MTCD/publications/PDF/trs461_web.pdf).
- [41] W. H. Bragg and R. Kleeman, “LXXIV. On the ionization curves of radium,” *London, Edinburgh, Dublin Philos. Mag. J. Sci.*, vol. 8, no. 48, pp. 726–738, 1904, doi: 10.1080/14786440409463246.
- [42] T. Kamada, “The characteristics of carbon-ion radiotherapy,” *Carbon-Ion Radiother. Princ. Pract. Treat. Plan.*, pp. 13–16, Jan. 2014, doi: 10.1007/978-4-431-54457-9\_2.
- [43] William R. Hendee, *Proton and Carbon Ion Therapy*. .
- [44] H. Tsujii, “History of charged particle radiotherapy,” *Carbon-Ion Radiother. Princ. Pract. Treat. Plan.*, pp. 3–10, Jan. 2014, doi: 10.1007/978-4-431-54457-9\_1.
- [45] N. Matsufuji, “Biophysical models and RBE,” *Carbon-Ion Radiother. Princ. Pract. Treat. Plan.*, p. 39, Jan. 2014, doi: 10.1007/978-4-431-54457-9\_5.
- [46] Y. Furusawa, “Heavy-ion radiobiology,” *Carbon-Ion Radiother. Princ. Pract. Treat. Plan.*, pp. 25–37, Jan. 2014, doi: 10.1007/978-4-431-54457-9\_4.
- [47] T. Inaniwa *et al.*, “Reformulation of a clinical-dose system for carbon-ion radiotherapy treatment planning at the National Institute of Radiological Sciences, Japan,” *Phys. Med. Biol.*, vol. 60, no. 8, pp. 3271–3286, 2015, doi: 10.1088/0031-9155/60/8/3271.
- [48] A. Wambersie *et al.*, “Isoeffective dose: A concept for biological weighting



- of absorbed dose in proton and heavier-ion therapies,” *Radiat. Prot. Dosimetry*, vol. 143, no. 2–4, pp. 481–486, 2011, doi: 10.1093/rpd/ncq410.
- [49] N. Kanematsu and T. Inaniwa, “Treatment planning of carbon-ion radiotherapy,” *Carbon-Ion Radiother. Princ. Pract. Treat. Plan.*, pp. 87–97, Jan. 2014, doi: 10.1007/978-4-431-54457-9\_11.
- [50] S. Fukuda, T. Furukawa, and Y. Iwata, “Beam-delivery systems,” *Carbon-Ion Radiother. Princ. Pract. Treat. Plan.*, pp. 53–64, Jan. 2014, doi: 10.1007/978-4-431-54457-9\_7.
- [51] T. Sato *et al.*, “Features of Particle and Heavy Ion Transport code System (PHITS) version 3.02,” *J. Nucl. Sci. Technol.*, vol. 55, no. 6, pp. 684–690, 2018, doi: 10.1080/00223131.2017.1419890.
- [52] M.- Cristy, “Mathematical Phantoms for Use in Reassessment of Radiation to Japanese Atomic-Bomb Survivors,” *Metab. Dosim. Res. Gr.*, pp. 1–55, 1985.
- [53] “Health effects of security scanners for passenger screening (based on X-ray technology),” doi: 10.2772/87426.

